History of Lomustine
From CeeNU® To Gleostine®
Prior to 2013, CeeNU® (lomustine) was manufactured by Bristol-Myers-Squibb but in limited quantities, resulting in short supply of this key component used in the treatment of brain cancer and Hodgkin’s lymphoma.
NextSource Pharmaceuticals recognized the medical importance of lomustine so in partnership with Corden Pharma, acquired the manufacturing rights from Bristol-Myers-Squibb and relaunched the product under the name Gleostine® the following year.
NextSource is committed to identifying drugs facing potential discontinuation or repeated short supply concerns that are vital in the application of a proven therapy choice by healthcare providers.